New Vivus board appoints Zook as CEO
This article was originally published in Scrip
Former AstraZeneca commercial head Anthony "Tony" Zook was appointed CEO of obesity drug maker Vivus as expected now that the Mountain View, California-based company's largest investor First Manhattan Co (FMC) controls a majority of the Vivus board of directors seats.
You may also be interested in...
Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.